Key terms
About ACXP
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACXP news
Mar 19
6:26am ET
Acurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic Partnerships
Mar 19
6:15am ET
Acurx price target lowered to $12 from $14 at H.C. Wainwright
Mar 18
4:08pm ET
Acurx files common stock offering, no amount given
Feb 28
6:39am ET
Buy Rating for Acurx Pharmaceuticals Amid Promising Phase 2 Results and Positive Regulatory Momentum
Jan 22
1:21pm ET
Analysts’ Top Healthcare Picks: Acurx Pharmaceuticals (ACXP), Champions Oncology (CSBR)
Jan 22
12:31pm ET
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Lisata Therapeutics (LSTA) and Acurx Pharmaceuticals (ACXP)
Jan 17
7:06am ET
Acurx announces results from ibezapolstat Phase 2b clinical trial
ACXP Financials
Key terms
Ad Feedback
ACXP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACXP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
